FDA Grants Priority Review for REZZAYO to Prevent Fungal Disease

CorMedix Therapeutics' supplemental New Drug Application for REZZAYO® (rezafungin for injection) has received priority review from the FDA. This sNDA seeks approval for preventing invasive fungal disease, with a target action date in Q1 2027. The drug is currently approved for treating candidemia and invasive candidiasis, and this expansion could offer a new prophylactic option.